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Abstract
Introduction The stroma is the supportive framework of biologic
tissue in the breast, consisting of various proteins such as the
proteoglycans, decorin and lumican. Altered expression of
decorin and lumican is associated with breast tumors. We
hypothesized that genetic variation in the decorin (DCN) and
lumican (LUM) genes may contribute to breast cancer.
Methods We investigated associations of 14 common
polymorphisms in the DCN and LUM genes with 798 breast
cancer cases and 843 controls from Mayo Clinic, MN, USA.
One polymorphism per gene with the strongest risk association
in the Mayo Clinic sample was genotyped in 4,470 breast
cancer cases and 4,560 controls from East Anglia, England
(Studies of Epidemiology and Risk Factors in Cancer Heredity
(SEARCH)).
Results In the Mayo Clinic sample, six polymorphisms were
associated with breast cancer risk (Ptrend  0.05). The
association with LUM rs2268578, evaluated further in
SEARCH, was positive, although the odds ratios (OR) were
weaker and not statistically significant. ORs were 1.4 (95%
confidence interval [CI], 1.1 to 1.8) for heterozygotes and 2.2
(95% CI, 1.1 to 4.3; P2 df = 0.002) for homozygotes in the Mayo
Clinic sample, and were 1.1 (95% CI, 0.9 to 1.2) for
heterozygotes and 1.4 (95% CI, 1.0 to 2.1; P2 df = 0.13) for
homozygotes in the SEARCH sample. In combined analyses,
the ORs were 1.1 (95% CI, 1.0 to 1.2) for heterozygotes and
1.6 (95% CI, 1.2 to 2.3; P2 df = 0.005) for homozygotes. Positive
associations for this polymorphism were observed for estrogen
receptor-positive tumors in both the Mayo Clinic sample (OR for
heterozygotes = 1.5, 1.1 to 1.9 and OR for homozygotes = 2.5,
1.2 to 5.3;P2 df = 0.001) and the SEARCH sample (OR for
heterozygotes = 1.0, 0.9 to 1.1 and OR for homozygotes = 1.6,
1.0 to 2.5; P2 df = 0.10). In combined analyses, the ORs were
1.1 (95% CI, 0.9 to 1.2) for heterozygotes and 1.9 (95% CI, 1.3
to 2.8; P2 df = 0.001) for homozygotes.
Conclusions Although LUM rs2268578 was associated with
breast cancer in the Mayo Clinic study, particularly estrogen
receptor-positive breast cancer, weaker and modest
associations were observed in the SEARCH sample. These
modest associations will require larger samples to adequately
assess the importance of this polymorphism in breast cancer.Page 1 of 11
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CGEMS: Cancer Genetic Markers of Susceptibility; DCN: decorin gene; 2 df: two degrees of freedom; ER, estrogen receptor; LUM: lumican gene; 
MAF: minor allele frequency; SEARCH, Studies of Epidemiology and Risk Factors in Cancer Heredity; SNP: single nucleotide polymorphism; UTR: 
untranslated region.
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Stromal changes are well documented in breast tumors [1,2]
and in preinvasive breast lesions [2,3], and are hypothesized
to play a role in breast cancer. The stroma may lead to morpho-
logic changes that manifest as tumors through a stromal reac-
tion or perturbation of epithelium [4] or, conversely, may play
an initial landscaping role in tumorigenesis independent of epi-
thelial neoplastic alterations [5].
The stroma is the supportive framework of biologic tissue con-
sisting of an extensive extracellular matrix that supports cells,
separates tissues and regulates intercellular communication.
The extracellular matrix is composed of different proteins:
decorin and lumican are members of the small leucine-rich
proteoglycan family of proteins and are involved in matrix
assembly and structure, and in the control of cell proliferation
[6]. Knockout mice deficient for either the decorin (DCN) gene
or the lumican (LUM) gene are viable, but show skin fragility,
marked reductions in tensile strength and loosely packed col-
lagen fibers with abnormal sheath diameters [7,8] – implicat-
ing the small leucine-rich proteoglycans as major regulators of
collagen fibril assembly that probably play a role in the devel-
opment of a barrier against cell penetration and infiltration of
macromolecules [6].
Recent evidence supports an anti-oncogenic role for decorin.
Injection of decorin protein into mammary carcinoma rodent
models resulted in a marked reduction in both primary tumor
growth and metastatic spread compared with animals injected
with vehicle alone [9]. Low levels of decorin protein in invasive
breast cancers have also been associated with larger tumor
size, shortened duration to progression and poor outcome
[10]. The role of lumican in carcinogenesis has been less well
studied. Immunohistochemical analyses of breast tissue
detected significantly higher lumican protein expression in
tumors than in adjacent normal tissue, yet significantly lower
decorin protein expression in tumors than in normal breast tis-
sue [11]. Positive associations between decorin and lumican
protein expression and mammographic density, a major risk
factor for breast cancer, have also been observed [12]. These
findings suggest that expression and/or activity of members of
the small leucine-rich proteoglycan family may affect breast
cancer risk.
Given the role of the stroma in breast cancer [1,2], the occur-
rence of genetic alterations in the stroma of breast tumors [13-
15] and the putative contribution of decorin and lumican to this
disease [10,11], we hypothesized, a priori, that common
genetic variation in the DCN and LUM genes is associated
with breast cancer risk. We evaluated this hypothesis using
data from a clinic-based case-control study of breast cancer,
with follow-up in a large British case-control study.
Materials and methods
Mayo Clinic study design and population
The Mayo Clinic Breast Cancer study is an Institutional Review
Board-approved, ongoing clinic-based case-control study ini-
tiated in February 2001 at Mayo Clinic, Rochester, MN, USA.
The study design has been presented previously [16,17].
Clinic attendance formed the sampling frame for Mayo Clinic
cases and controls.
Consecutive cases were women aged 18 years or older with
histologically confirmed primary invasive breast carcinoma
who were recruited within 6 months of their date of diagnosis.
Women with a history of cancer (excluding nonmelanoma skin
cancer) were ineligible. Cases lived in the six-state region that
defines Mayo Clinic's primary service population (Minnesota,
Iowa, Wisconsin, Illinois, North Dakota and South Dakota).
Although Mayo Clinic is widely perceived to be a specialty ter-
tiary care facility, it also provides primary care for over 500,000
individuals per year.
Control individuals without prior history of cancer (other than
nonmelanoma skin cancer) were frequency matched on age
(5-year age category), race and six-state region of residence
to cases. Controls were recruited from the outpatient practice
of the Divisions of General Internal Medicine and Primary Care
Internal Medicine at Mayo Clinic, where they were seen for
routine medical examinations.
Written informed consent was obtained from all participants.
Case participation was 69% and control participation was
71%. The present investigation genotyped Caucasian women
(99% of study participants) enrolled up to 30 June 2005, rep-
resenting 798 cases and 843 controls.
Both the cases and controls completed a self-administered
questionnaire comprised of known or suspected breast can-
cer risk factors, and they provided blood samples from which
genomic DNA was isolated using the Gentra AutoPure LS
Purgene salting out methodology (Gentra, Minneapolis, MN,
USA). Quantities of 250 g genomic DNA were adjusted to
50 g/l before genotyping and were verified using the
PicoGreen dsDNA quantitation kit (Molecular Probes, Inc.,
Eugene, OR, USA). The samples were bar coded to ensure
accurate and reliable sample processing and storage.
SNP selection, genotyping and quality control
All SNPs in the DCN and LUM genes within 5 kb of the largest
cDNA isoform (genome build 35) were selected from the Cau-
casian samples within the HapMap Consortium's release 21
[18]. We applied the ldSelect program [19] to bin SNPs with
minor allele frequency (MAF)  0.05 and pairwise linkage dis-
equilibrium threshold of r2  0.80. tagSNPs were selected
from these bins that met the criteria for predicted likelihood of
successful genotyping using the Illumina GoldenGate Assay™
quality score metrics (Illumina Corporation, San Diego, CA,Page 2 of 11
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kb upstream, 5' UTR, 3' UTR or nonsynonymous) with MAF 
0.05 identified in Ensembl version 34 (Ensembl, European
Bioinformatics Institute/Wellcome Trust Sanger Institute,
Wellcome Trust Genome Campus, Hinxton, Cambridgeshire,
UK). Eight SNPs in DCN (including six functional SNPs) and
six SNPs in LUM (including three functional SNPs) were iden-
tified and examined in the Mayo Clinic study based on these
two methods of selection.
The DCN and LUM SNPs were assayed at Illumina Corpora-
tion (San Diego, CA, USA) using the GoldenGate Assay™ on
the Illumina BeadLab [20-22] as part of a larger Mayo Clinic
genetic association study. Successful genotyping was
achieved for all 14 selected SNPs in the 798 cases and 843
controls. All but one of the 14 SNPs had MAF  0.05 among
the Mayo controls (Table 1). Concordance between 100
duplicate samples was >99.99% for all assays.
SEARCH replication study population
Studies of Epidemiology and Risk Factors in Cancer Heredity
(SEARCH), an ongoing population-based study of cases with
invasive breast cancer ascertained through the Eastern Can-
cer Registration and Information Centre in England [23], was
used as a second, independent study to evaluate significant
breast cancer findings in the Mayo Clinic study. All women
diagnosed after 1990 in the East Anglia region (median age =
51 years, range = 25 to 69 years) were eligible, with approxi-
mately 65% of eligible breast cancer cases enrolled. Unaf-
fected female controls (median age = 65, range = 45 to 81
years) from the same geographic region were randomly
selected from the European Prospective Investigation into
Cancer and Nutrition -Norfolk component of the European
Prospective Investigation into Cancer and Nutrition in East
Anglia, with 41% participation. Over 98% of cases and con-
trols were white Europeans. The SEARCH study has been
used extensively to evaluate associations between breast can-
cer risk and SNPs in various genes [23] and as part of a
genome-wide association study for breast cancer [16].
Evaluation of the Mayo Clinic findings for DCN rs3138165
and LUM rs2268578, the SNPs with the most significant
associations with risk in each gene, was performed in the
SEARCH study. These SNPs were selected for their strength
of associations (point estimates and number of cases with two
copies of the minor allele) with breast cancer risk to genotype
in the SEARCH study comprising 4,470 cases and 4,560
controls with a 5' nuclease assay (Taqman®) using the ABI
PRISM 7900 HT Sequence Detection System according to
manufacturer's instructions (Applied Biosystems, Foster City,
CA, USA). Primers and probes were supplied directly by
Applied Biosystems [24] as Assays-by-Design™. Successful
genotyping was achieved for 98.6% of DNA samples.
Statistical analysis
Genotypes from the Mayo Clinic cases and controls were
used to estimate allele frequencies. Among control subjects
only, the genotypes were compared with those expected
Table 1
Genetic polymorphisms in the decorin (DCN) and lumican (LUM) genes and minor allele frequencies (MAFs) among 843 Caucasian 
controls, Mayo Clinic 2001 to 2005
Gene Location rsID Polymorphic region Amino acid change MAF (controls)
DCN 12q21.33 rs7441 Ex8 G/A 3' UTR 0.06
rs3138268 Ex7 G/A Met268Thr 0
rs516115 IVS3 A/G 0.26
rs3138165a IVS1 G/A 5' UTR 0.06
rs2070985a IVS1 G/C 5' UTR 0.06
rs741212 IVS1 A/G 5' UTR 0.12
rs13312816a IVS1 A/T 0.06
rs10492230 G/A 5' upstream 0.16
LUM 12q21.3–q22 rs1920790 A/C 3' downstream 0.12
rs17714469 G/A 3' downstream 0.10
rs10745553 IVS2 G/C 0.15
rs2268578 IVS2 G/A 0.11
rs10859110 IVS1 G/A 0.22
rs17018765 A/G 5' upstream 0.06
aLinkage disequilibrium r2  0.98 for all pairwise combinations of these SNPs.Page 3 of 11
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ness-of-fit test; no departures were found.
Pairwise linkage disequilibrium between SNPs was estimated
with r2 values [25] using Haploview [26]. Individual SNP asso-
ciations for breast cancer risk were assessed using uncondi-
tional logistic regression to estimate the odds ratios (ORs) and
95% confidence intervals (CIs). Analyses compared women
with one copy and two copies of the minor allele with women
with no copies using a two-degrees-of-freedom (2 df) model.
We then assessed the dose-response effect of the SNP using
an ordinal (log-additive) model.
Haplotype analyses were performed to identify whether the
association with breast cancer risk could be informed further
by phased combinations of alleles within each gene. Such
combinations of alleles on a single chromosome can provide
information about the possible presence of nearby breast can-
cer risk alleles that were not genotyped. Haplotype frequen-
cies for each gene were estimated using all SNPs within the
gene, and associations between individual haplotypes and
breast cancer risk were evaluated compared with all other
haplotypes combined. Haplotype frequencies for each gene
were estimated using all SNPs within the gene, and a global
haplotype score test of no association between haplotypes
and breast cancer risk was evaluated at the gene level by the
method proposed by Schaid and colleagues [27]. When the
global haplotype score test suggested significance at the
gene level, individual haplotype-specific associations for risk of
breast cancer were compared with all other haplotypes com-
bined.
In the SEARCH study, age-adjusted single-SNP associations
were conducted using unconditional logistic regression under
one-copy/two-copy and ordinal genetic models as described
above.
In secondary analyses in both the Mayo Clinic and SEARCH
studies, we stratified the data to evaluate the risk of breast
cancer attributable to LUM rs2268578 in cases with estrogen
receptor (ER)-positive and ER-negative tumors compared with
control subjects because of recent reports of differential lumi-
can protein expression by tumor ER status [10,28].
Analyses were implemented using Haplo.stats [29], the SAS
software system (version 8, 1999; SAS Institute, Cary, NC,
USA) and the S-Plus software system (version 7.05, 2005;
Insightful Corp., Seattle, WA, USA). Given prior hypotheses
that SNPs in the DCN and LUM genes are associated with
breast cancer risk, corrections for multiple testing were not
performed. Two-tailed P  0.05 was considered statistically
significant.
Results
Eight tagSNPs in DCN representing 21 individual SNPs and
six tagSNPs in LUM representing 15 individual SNPs were
identified from the HapMap (Table 1 and Figure 1). Of eight
tagSNPs genotyped in DCN, three were highly correlated
(rs3138165, rs2070985 and rs13312816: pairwise r2 
0.98). This redundancy resulted from genotyping all putative
functional SNPs in addition to the tagSNPs; only data from
one DCN tagSNP (rs3138165) are therefore shown in subse-
quent analyses. Further, another DCN tagSNP (rs3138268)
had MAF = 0 among control subjects and was excluded from
further analyses.
The Mayo Clinic cases and controls were adequately matched
on age and region of residence, but differed in distribution by
menopausal status, postmenopausal hormone use, age at
menarche and smoking (Table 2). Covariates were evaluated
for confounding in statistical models, and there was no appre-
ciable difference in risk estimates of association when these
covariates were excluded. The results for risk models are
therefore presented adjusted for age and region of residence.
Breast cancer risk analyses
In the individual SNP analyses, three SNPs in DCN and three
SNPs in LUM were associated with breast cancer risk in the
Mayo Clinic sample: results of the one-copy/two-copy genetic
model and of the ordinal model are presented in Table 3. The
ORs associated with each copy of the minor allele varied
slightly for DCN rs7441 (OR = 1.3, 95% CI = 1.0 to 1.7; Ptrend
= 0.05), DCN rs516115 (OR = 1.2, 95% CI = 1.0 to 1.4;
Ptrend = 0.03) and DCN rs3138165 (OR = 1.3, 95% CI = 1.0
to 1.8; Ptrend = 0.03). In LUM, the associations with each copy
of the minor allele were similar for LUM rs2268578 (OR = 1.4,
95% CI = 1.2 to 1.8; Ptrend = 0.0003), LUM rs10859110 (OR
= 1.3, 95% CI = 1.1 to 1.5; Ptrend = 0.001) and LUM
rs17018765 (OR = 1.3, 95% CI = 1.0 to 1.7; Ptrend = 0.04).
At the gene level, only LUM (P = 0.01) showed evidence of a
significant association across haplotypes for breast cancer
risk (Table 4). Of nine haplotypes observed in LUM, one six-
SNP haplotype (haplotype 2a) – accounting for 71% of all
estimated haplotypes – was associated with decreased
breast cancer risk (P = 0.01), while two separate haplotypes
with 6% (haplotype 2 h) and 7% (haplotype 2i) frequency
were associated with increased risk (P  0.03).
The DCN rs3138165 and LUM rs2268578 SNPs were gen-
otyped in the SEARCH study. The association of DCN
rs3138165 in the Mayo Clinic sample was not confirmed in
the SEARCH study, whereas LUM rs2268578 was positively
associated with breast cancer risk but the ORs attenuated and
did not reach statistical significance (Table 5). Compared with
women with no copies of the minor allele in LUM rs2268578,
women with two copies showed the greatest risk for breast
cancer in both the Mayo Clinic sample (OR = 2.2, 95% CI =Page 4 of 11
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= 1.4, 95% CI = 1.0 to 2.1; P2 df = 0.13). When the data from
the two studies were pooled in age-adjusted and study-
adjusted models, LUM rs2268578 was associated with
increased risk among heterozygotes (OR = 1.1, 95% CI = 1.0
to 1.2) and homozygotes (OR = 1.6, 95% CI = 1.2 to 2.3; P2
df = 0.005) (Table 5). The corresponding per-minor allele risk
was 1.1 (95% CI = 1.0 to 1.2; Ptrend = 0.004). These data sug-
gest that LUM rs2268578 or a variant in strong linkage dise-
quilibrium with rs2268578 may be a risk factor for breast
cancer.
Estrogen receptor subgroup analyses
Women with two copies compared with no copies of the minor
allele in LUM rs2268578 were at higher risk, compared with
control individuals, of ER-positive breast cancer in both the
Mayo Clinic study (OR = 2.5, 95% CI = 1.2 to 5.3; P2 df =
0.001) and the SEARCH study (OR = 1.6, 95% CI = 1.0 to
2.5; P2 df = 0.10) (Table 6). The per-minor allele risks were 1.5
(95% CI = 1.2 to 1.9; Ptrend = 0.0003) in the Mayo Clinic sam-
ple and 1.1 (95% CI = 0.9 to 1.2; Ptrend = 0.29) in the
SEARCH sample. In pooled age-adjusted and study-adjusted
analyses, LUM rs2268578 was associated with ER-positive
tumors among heterozygotes (OR = 1.1, 95% CI = 0.9 to 1.2)
and homozygotes (OR = 1.9, 95% CI = 1.3 to 2.8; P2 df =
0.001). The corresponding per-minor allele risk was 1.1 (95%
CI = 1.0 to 1.3; Ptrend = 0.01).
The number of ER-negative cases was small in both samples
and associations with breast cancer were not evident (Table
6). These data may suggest that the associations observed
from the main effects models in both studies (Table 5) are due
to the findings from ER-positive tumors. Almost one-half of
SEARCH study tumors and one-quarter of Mayo Clinic
tumors, however, could not be classified – precluding a defin-
itive interpretation of the results, particularly for ER-negative
breast cancer.
Discussion
We found a positive association between LUM rs2268578
and breast cancer risk in two large independent case-control
studies, although the association in the SEARCH sample was
attenuated and did not reach statistical significance. Two cop-
ies of the minor allele in LUM rs2268578 were associated
Figure 1
Linkage disequilibrium plots for polymorphisms in the DCN and LUM genesge disequ librium plots for polymorphisms in the DCN and LUM genes. Linkage disequilibrium (LD) plots for polymorphisms in the Mayo 
Clinic sample, 2001 to 2005, for (a) the decorin (DCN) gene and (b) the lumican (LUM) gene. Shaded regions indicate strength of LD between 
pairwise combinations of polymorphisms (white, r2 = low LD; black, r2 = near-perfect LD). Numbers in squares indicate estimates of the pairwise r2. 
DCN SNP rs3138268 had minor allele frequency = 0 (absent in figure), and DCN SNPs rs3138165, rs2070985 and rs13312816 had pairwise r2 
 0.98: only rs3138165 was included in the statistical analyses.Page 5 of 11
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Table 2
Demographic, personal and lifestyle characteristics among 1,641 Caucasian breast cancer cases and controls, Mayo Clinic 2001 to 
2005
Cases (n = 798) Controls (n = 843)
Characteristic Level n %a n %
Age (years) 20 to 39 56 7 48 6
40 to 49 192 24 166 20
50 to 59 224 28 274 32
60 to 69 195 24 207 25
70+ 131 16 148 18
State of residence Minnesota 502 63 552 66
Wisconsin 69 9 78 9
Iowa 128 16 147 17
North Dakota/South Dakota 52 6 41 5
Illinois 47 6 25 3
Body mass index (kg/m2) Mean (standard deviation) 28 8 27 8
Family historyb Yes 366 47 345 43
Postmenopausal status Yes 480 64 579 72
Age at menarche (years) <12 132 18 122 16
12 224 31 184 24
13 218 30 238 32
 14 154 21 209 28
Oral contraceptive use 0 months 266 35 243 31
1 to 48 months 185 24 189 24
48+ months 310 41 345 44
Postmenopausal hormone use 0 months 430 58 366 49
1 to 60 months 131 18 160 22
60+ months 184 25 216 29
Age at first birth (years) Nulliparous 97 13 128 16
 20 years 173 22 158 20
>20 years 501 65 514 64
Smoking (pack years) None 467 63 500 66
 4 years 46 6 67 9
>4 years 231 31 192 25
Alcohol consumption Never 92 12 94 12
Monthly 332 43 327 41
Weekly 259 34 299 37
Daily 83 11 79 10
aPercentages may not total 100 due to missing data. bFamily history in first-degree or second-degree relative with breast cancer or ovarian cancer.
Available online http://breast-cancer-research.com/content/10/6/R98with an average 60% increased risk of breast cancer com-
pared with women with no copies, and the data suggest
increased risk for ER-positive tumors. DCN rs3138165 was
positively associated with breast cancer risk in the Mayo Clinic
sample but the finding was not confirmed in the SEARCH
sample. Haplotypes from each gene were also associated with
breast cancer risk in the Mayo Clinic sample.
The weaker association of LUM rs2268578 with breast can-
cer risk in the SEARCH sample may be due to a lack of causal
association of this SNP with breast cancer, or the results may
be a more valid estimate of effect. It is not uncommon for rep-
licated findings to report ORs for the variant homozygote that
are weaker compared with the initial study's findings, a phe-
nomenon known as winner's curse [30]. Furthermore, a small
sample size can frequently result in insufficient power to
detect minor contributions of one or more alleles [30] – as we
observed with the results from the SEARCH sample.
In post hoc evaluation we also compared our results for LUM
rs2268578 with those from the Cancer Genetic Markers of
Susceptibility (CGEMS) genome-wide association study of
breast cancer risk among 1,145 postmenopausal breast can-
cer cases and 1,142 controls of European ancestry from the
Nurses' Health Study [31,32]. When restricted to postmeno-
pausal women, the associations with breast cancer risk were
weaker but remained positive in the Mayo Clinic and SEARCH
samples; however, in the CGEMS data, women with one copy
(OR = 1.1) or two copies (OR = 0.9, P2 df = 0.52), compared
with no copies, of the minor allele were not at risk of breast
cancer despite similar MAF = 0.12 among controls. The
CGEMS data did not report ER-positive or ER-negative
Table 3
Odds ratios (OR) and 95% confidence intervals (CI)a between polymorphisms in the decorin (DCN) and lumican (LUM) genes and 
breast cancer risk among 1,641 Caucasian subjectsb, Mayo Clinic 2001 to 2005
Polymorphism/
rsID
MAF Homozygotes common allele 
(referent OR = 1)
Heterozygotesc Homozygotes rare allelec Per allele P trend
Cases Controls Cases Controls OR 
(95% CI)
Cases Controls OR 
(95% CI)
OR 
(95% CI)
DCN
rs7441 0.06 675 744 119 95 1.3 
(1.0 to 1.8)
4 4 1.2 
(0.3 to 4.7)
1.3 
(1.0 to 1.7)
0.05
rs516115 0.26 397 470 336 316 1.2 
(1.0 to 1.5)
65 57 1.3 
(0.9 to 2.0)
1.2 
(1.0 to 1.4)
0.03
rs3138165 0.06 668 741 123 98 1.4 
(1.0 to 1.8)
6 4 1.8 
(0.5 to 6.3)
1.3 
(1.0 to 1.8)
0.03
rs741212 0.12 616 662 167 167 1.1 
(0.8 to 1.4)
15 14 1.2 
(0.6 to 2.5)
1.1 
(0.9 to 1.3)
0.51
rs10492230 0.16 557 589 216 231 1.0 
(0.8 to 1.2)
25 23 1.2 
(0.7 to 2.1)
1.0 
(0.8 to 1.2)
0.88
LUM
rs1920790 0.12 594 653 188 180 1.1 
(0.9 to 1.4)
16 10 1.8 
(0.8 to 3.9)
1.2 
(0.9 to 1.4)
0.13
rs17714469 0.10 647 683 141 152 1.0 
(0.7 to 1.2)
10 8 1.3 
(0.5 to 3.3)
1.0 
(0.8 to 1.3)
1.0
rs10745553 0.15 559 613 214 212 1.1 
(0.9 to 1.4)
24 17 1.6 
(0.8 to 3.0)
1.1 
(0.9 to 1.4)
0.14
rs2268578 0.11 567 661 207 167 1.4 
(1.1 to 1.8)
23 13 2.2 (1.1 to 
4.3)d
1.4 
(1.2 to 1.8)
0.0003
rs10859110 0.22 418 517 331 283 1.4 
(1.2 to 1.7)
49 43 1.4 (0.9 to 
2.2)d
1.3 
(1.1 to 1.5)
0.001
rs17018765 0.06 673 744 121 95 1.4 
(1.0 to 1.8)
4 4 1.2 
(0.3 to 4.7)
1.3 
(1.0 to 1.7)
0.04
MAF, minor allele frequency. aAdjusted for age and region of residence (Minnesota, Iowa, Wisconsin, Illinois, North Dakota and South Dakota). b798 
cases and 843 controls. cReferent (OR = 1) is homozygous common allele group. dTwo-degrees-of-freedom test, P = 0.002.Page 7 of 11
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the range 1.1 to 1.5, then a much larger study than SEARCH
or CGEMS would be needed to have sufficient power to rep-
licate the association at either the conventional (P  0.05) or
the genome-wide (P  10-7) level of significance. It should be
noted that, even in the combined Mayo Clinic and SEARCH
samples, there were only 108 cases and 75 controls
homozygous for the minor allele. Comparable information from
CGEMS is not available. It remains possible that the distribu-
tion of other exposures – for example, 60% of Mayo Clinic
cases did not use postmenopausal hormones versus <30% in
the Nurses' Health Study [33] – may also explain the differ-
ences in genetic associations with CGEMS.
The hypothesis that genetic variation in LUM is associated
with breast cancer is based on a recent series of reports by
Watson and colleagues of altered regulation of LUM in human
breast tumors [10,11]. Using in situ hybridization and western
blot techniques, LUM mRNA levels were significantly higher
(P < 0.0001) in stroma associated with breast carcinoma
compared with stroma associated with adjacent normal tissue
in the same woman [11]. In the present study, the observed
risk associated with breast cancer from the LUM intronic SNP
rs2268578 or from a SNP in strong linkage disequilibrium with
rs2268578 may be consistent with increased protein expres-
sion of lumican in the study by Leygue and colleagues [11], if
it represents a negative host response contributing to early
tumor development through increased proteolysis or altered
lumican deposition that precedes disorganized collagenous
stroma [11]. Elucidation of the functional impact of the LUM
SNP(s) is needed in order to provide insight into the effects on
risk.
Associations with breast cancer risk for the DCN and LUM
genes were observed with haplotype analyses in the Mayo
Clinic sample. Of note, the three haplotypes in LUM that were
associated with breast cancer risk had in common the G allele
at position 2 (rs17714469) and a graduated change in the
Table 4
Gene-levela analysis of the decorin (DCN) and lumican (LUM) genes with breast cancer risk among 1,641 Caucasian subjectsb, Mayo 
Clinic 2001 to 2005
Gene/haplotype Global haplotype score test P 
value
Estimated haplotype 
frequency
Individual haplotype score 
testc
Individual haplotype P valued
DCNe 0.18
1a: AAAAC 0.73 -2.19 0.03
1b: AGAAT 0.05 -0.65 0.52
1c: GGAAC 0.001 0.38 0.70
1d: AGAGT 0.12 0.59 0.55
1e: AGGAC 0.004 0.82 0.41
1f: AGAAC 0.03 1.82 0.07
1g: GGGAC 0.07 1.92 0.05
LUMf 0.01
2a: AGGGGA 0.71 -2.44 0.01
2b: CGGGGA 0.05 -0.74 0.46
2c: CGGGAA 0.004 -0.04 0.97
2d: AACGAA 0.10 0.42 0.67
2e: AGGGAA 0.003 0.89 0.37
2f: CGGAAA 0.01 1.08 0.28
2g: AGGAAA 0.003 1.38 0.17
2h: AGCAAA 0.06 2.18 0.03
2i: CGGAAG 0.07 2.29 0.02
aAdjusted for age and region of residence (Minnesota, Iowa, Wisconsin, Illinois, North Dakota and South Dakota). b798 cases and 843 controls. 
cScore statistics comparing haplotype of interest with all other haplotypes combined. Negative values imply decreased risk of breast cancer, 
whereas positive values imply increased risk. dP value comparing haplotype of interest with all other haplotypes combined. eHaplotype-forming 
SNPs in DCN are rs7441 (A/G), rs516115 (A/G), rs3138165 (A/G), rs741212 (A/G), rs10492230 (A/G). fHaplotype-forming SNPs in LUM are 
rs1920790 (A/C), rs17714469 (G/A), rs10745553 (G/C), rs2268578 (G/A), rs10859110 (G/A), rs17018765 (A/G).Page 8 of 11
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rs10859110 and rs17018765) from GGA (haplotype 2a),
associated with decreased risk, to AAA (haplotype 2h) and
AAG (haplotype 2g), each associated with increased risk. It is
possible that the association between breast cancer risk and
these inferred haplotypes may be attributable to LUM
rs2268578 or a SNP in strong linkage disequilibrium with
rs2268578 because this single SNP was also associated with
risk in both the Mayo Clinic and SEARCH samples. Further
association testing in this chromosomal region – based on
genotypes from a denser marker set – is required, however, in
order to fully understand the nature of the relationship.
The increased risk of breast cancer from LUM rs2268578 may
be due to the positive association with ER-positive breast
tumors in both the Mayo Clinic and SEARCH samples,
although the analyses were underpowered and were not
based on a priori hypotheses. The association between lumi-
can expression and ER-positive breast tumors is supported by
the findings from two studies [10,28]. Troup and colleagues
[10] found that a greater number of ER-positive tumors (n =
99) compared with ER-negative tumors (n = 6) had lumican
protein expression  25th percentile among 140 women with
breast cancer (P = 0.002). Mackay and colleagues [28] eval-
uated gene microarray expression profiles in biopsies
obtained from 34 women with primary ER-positive breast can-
cer before and after a 2-week intervention of aromatase inhib-
itor treatment. Among the 2,418 genes with the greatest
variability in expression, the LUM gene was the most highly
upregulated by a factor, on average, of 2.9-fold following aro-
matase inhibitor treatment, and the DCN gene was upregu-
lated by a factor of 2.3. Collectively, these data suggest a
potential mechanistic link between LUM expression and ER-
positive tumors, which requires further investigation.
The strengths of the present study include the incorporation of
a second, independent large sample of cases and controls to
confirm initial findings. Our study populations were enrolled
from defined regions, were of Caucasian ancestry and were
less probably influenced by population stratification [34]. This
does not necessarily, however, allow generalization of the
observed association with breast cancer to other ethnic/racial
populations [35]. One limitation is that the classification of
tumors by ER status was not centrally reviewed and a large
Table 5
Odds ratios (OR) and 95% confidence intervals (CI)a between polymorphisms in the decorin (DCN) and lumican (LUM) genes and 
breast cancer risk among 1,641 Caucasian subjects (Mayo Clinic 2001 to 2005) and 9,030 Caucasian subjects (SEARCH study 1990 
2005)b
DCN rs3138165 LUM rs2268578
Model Mayo Clinic sample 
(MAF = 0.06)
SEARCH sample 
(MAF = 0.07)
Pooled 
Mayo 
Clinic + 
SEARCH 
sample
Mayo Clinic sample 
(MAF = 0.11)
SEARCH sample 
(MAF = 0.12)
Pooled 
Mayo 
Clinic + 
SEARCH 
sample
Cases/
controls
OR 
(95% CI)
Cases/
controls
OR 
(95% CI)
OR 
(95% CI)
Cases/
controls
OR 
(95% CI)
Cases/
controls
OR 
(95% CI)
OR 
(95% CI)
General
0 copy 668/741 1.0 
(referent)
3,801/
3,965
1.0 
(referent)
1.0 
(referent)
567/661 1.0 
(referent)
3,306/
3,506
1.0 
(referent)
1.0 
(referent)
1 copy 123/98 1.4 
(1.0 to 
1.8)
547/558 1.0 
(0.9 to 
1.2)
1.1 
(0.9 to 
1.2)
207/167 1.4 
(1.1 to 
1.8)
972/980 1.1 
(0.9 to 
1.2)
1.1 
(1.0 to 
1.2)
2 
copies
6/4 1.8 
(0.5 to 
6.3)
19/20 0.8 
(0.4 to 
1.7)
1.1 
(0.6 to 
2.1)
23/13 2.2 
(1.1 to 
4.3)
85/62 1.4 
(1.0 to 
2.1)
1.6 
(1.2 to 
2.3)
P valuec 0.08 0.87 0.61 0.002 0.13 0.005
Ordinal 1.3 
(1.0 to 
1.8)
1.0 
(0.9 to 
1.1)
1.1 
(0.9 to 
1.2)
1.4 
(1.2 to 
1.8)
1.1 
(1.0 to 
1.2)
1.1 
(1.0 to 
1.2)
P trend 0.03 0.96 0.32 0.0003 0.10 0.004
MAF, minor allele frequency. aMayo Clinic sample adjusted for age and region of residence (Minnesota, Iowa, Wisconsin, Illinois, North Dakota 
and South Dakota); SEARCH sample adjusted for age; pooled Mayo Clinic + SEARCH sample adjusted for age and study. b798 cases and 843 
controls (Mayo Clinic sample), and 4,470 cases and 4,560 controls (SEARCH sample). cTwo-degrees-of-freedom test.Page 9 of 11
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strong conclusion of the association of the LUM SNP by ER
status. Furthermore, it remains possible that the other variants
in DCN and LUM that were not selected for genotyping in
SEARCH may also influence breast cancer risk.
Conclusion
Although LUM rs2268578 was associated with breast cancer
in the Mayo Clinic study, particularly ER-positive breast can-
cer, weaker and modest associations were observed in the
SEARCH sample. Evaluation of this SNP in a larger study
(such as the Breast Cancer Association Consortium) along
with functional studies will be needed to adequately assess
the importance of this SNP in breast cancer.
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